Retatrutide vs Tesofensine

Retatrutide and Tesofensine are both research compounds studied for their effects on weight regulation and metabolic health, yet they operate through fundamentally different biological pathways. Retatrutide, a triple hormone receptor agonist, leverages gut hormone signaling to modulate appetite and energy expenditure, while Tesofensine, a triple monoamine reuptake inhibitor, targets central neurotransmitter systems to suppress appetite and increase metabolic rate. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

Retatrutide is a first-in-class investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. In the Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), the 12 mg dose achieved a mean body weight reduction of 24.2% at 48 weeks, with 100% of participants achieving at least 5% weight loss. Multiple Phase 3 TRIUMPH trials are ongoing; TRIUMPH-4 (Dec 2025) reported average weight loss up to 71.2 lbs with additional osteoarthritis pain relief. Expected FDA approval is 2027–2028. Key claims include unprecedented weight loss in Phase 2, Phase 3 confirmation of efficacy with osteoarthritis benefit, and improved glycemic control in type 2 diabetes.

Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Alzheimer's and Parkinson's disease. Phase 2 trials demonstrated approximately 10% body weight loss over 24 weeks, making it one of the most effective weight loss agents studied to date. It is not technically a peptide but is frequently discussed alongside peptide-based weight loss therapies. The compound was developed by NeuroSearch A/S and later licensed to Saniona, which is pursuing Phase 3 trials.

Key claims: Produces significant weight loss (~10% body weight); Suppresses appetite and reduces caloric intake; Increases resting metabolic rate.

These compounds target overlapping but distinct research areas. Retatrutide is primarily investigated for weight management and metabolic health, including glycemic control in type 2 diabetes and potential benefits in osteoarthritis. Tesofensine, while also studied for weight loss and appetite suppression, has a broader historical context in neurodegenerative disease research. Both are under investigation for their effects on energy balance, but their mechanisms—peripheral hormonal versus central neurotransmitter modulation—lead to different safety profiles and research applications.

Retatrutide: Gastrointestinal side effects are dose-related, occurring in 13–63% of participants across dose groups, including nausea, vomiting, diarrhea, and constipation. Most events are mild to moderate and partially mitigated by a lower starting dose (2 mg vs. 4 mg initial dose). Dose-dependent heart rate increases peak at 24 weeks and decline thereafter. Tesofensine: Phase 2 trials reported increased heart rate (5–8 bpm) and blood pressure elevation at higher doses. Common side effects include dry mouth, insomnia, constipation, nausea, and diarrhea. Psychiatric effects such as anxiety and mood changes have been reported, consistent with its mechanism as a monoamine reuptake inhibitor.